Sit Investment Associates Inc. Has $81,000 Stake in Zimmer Biomet Holdings, Inc. $ZBH

Sit Investment Associates Inc. reduced its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 97.7% in the fourth quarter, HoldingsChannel.com reports. The firm owned 900 shares of the medical equipment provider’s stock after selling 37,858 shares during the period. Sit Investment Associates Inc.’s holdings in Zimmer Biomet were worth $81,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZBH. DV Equities LLC purchased a new position in shares of Zimmer Biomet during the fourth quarter valued at approximately $25,000. Monetary Solutions Ltd purchased a new stake in Zimmer Biomet in the 4th quarter valued at $30,000. Gen Wealth Partners Inc purchased a new stake in Zimmer Biomet in the 4th quarter valued at $31,000. Flagship Harbor Advisors LLC bought a new position in Zimmer Biomet during the 4th quarter valued at $32,000. Finally, Grove Bank & Trust lifted its stake in Zimmer Biomet by 431.6% during the 4th quarter. Grove Bank & Trust now owns 404 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 328 shares in the last quarter. Institutional investors own 88.89% of the company’s stock.

Insider Activity

In other Zimmer Biomet news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider directly owned 27,251 shares in the company, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.28% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on ZBH shares. JPMorgan Chase & Co. reduced their target price on shares of Zimmer Biomet from $100.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a report on Wednesday, April 29th. Truist Financial reaffirmed a “hold” rating and issued a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Barclays decreased their price objective on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research note on Wednesday, April 29th. Finally, Stifel Nicolaus dropped their target price on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating on the stock in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus target price of $102.70.

Zimmer Biomet Stock Up 0.2%

ZBH opened at $88.13 on Friday. Zimmer Biomet Holdings, Inc. has a twelve month low of $79.12 and a twelve month high of $108.29. The company’s 50-day moving average price is $87.24 and its two-hundred day moving average price is $90.13. The stock has a market cap of $17.05 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 2.59 and a beta of 0.47. The company has a quick ratio of 0.95, a current ratio of 1.73 and a debt-to-equity ratio of 0.50.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. The company had revenue of $2.09 billion during the quarter, compared to analyst estimates of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s quarterly revenue was up 9.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, equities analysts expect that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date of this dividend is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.